Table 3. Baseline clinical data of patients with RA in the REAL study (n = 1116).
| Clinical data | Absolute value or % (n) |
|---|---|
| Age, years (mean ± SD) | 56.7 ± 11.4 |
| Female gender (%) | 998 (89.5%) |
| Study time, years (mean ± SD) | 8 ± 4.2 |
| Ethnicity/race/color (%) | |
| • White | 634 (56.8%) |
| • Black | 122 (10.9%) |
| • Pardoa | 349 (31.2%) |
| Symptom’s duration, years (mean ± SD) | 14.75 ± 7.8 |
| Diagnostic time interval, months (mean ± SD) [median (IQR)] | 32 ±51 12 (6–36) |
| Disease duration, years (mean ± SD) [median (IQR)] | 12.6 ± 7.6 12.7 (0.7–56.9) |
| Positive rheumatoid factor (%) | 78.5% (n = 1098) |
| Positive anti-citrullinated peptide antibody (%) | 76.8% (n = 479) |
| Erosive disease (%) | 54.9 (n = 1095) |
| Fibromyalgia (%) | 154 (13.7%) |
| Current smoking (%) | 121 (10.8%) |
| Medications: | |
| • Synthetic DMARD | 1031 (90,9%) |
| • Biological DMARD | 398 (35.7%) |
| • Biological DMARD monotherapy | 62 (5.6%) |
| • Glucocorticoids | 528 (47,4%) |
| Painb (0–100) [median (IQR)] | 40 (0–100) (n = 1116) |
| Fatigue (0–100) [median (IQR)] | 40 (0–100) (n = 1116) |
| Global health assessment (0–100) | 38 (0–100) (n = 1116) |
| ESR median (IQR) | 21 (10–40) (n = 925) |
| CRP median (IQR) | 0.67 (0.25–1.78) (n = 947) |
| HAQ median (IQR) | 0.875 (0.25–1.5) (n = 1112) |
| DAS28-CRP median (IQR) | 3.04 (2.23–4.21) (n = 937) |
| DAS28-ESR median (IQR) | 3.52 (2.55–4.51) (n = 925) |
| SDAI median (IQR) | 10.59 (4.47–20.20) (n = 943) |
| CDAI median (IQR) | 9 (3.7–18.89) (n = 1114) |
a Mixed white and black ethnicities.
b Patient global assessment.
DMARDS: disease -modifying anti-rheumatic drugs; ERS: erythrocyte sedimentation rate; CRP: C- reactive protein; HAQ: health assessment questionnaire; DAS28-CRP: Disease Activity Score 28- C reactive protein; DAS28-ESR: Disease Activity Score 28 -erythrocyte sedimentation rate; SDAI: Simplified Activity Index; CDAI: Clinical Activity Index.